Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy, with a response rate of 20% of patients and for this reason an efficient treatment is still a challenge. Platinum-based chemotherapy in association with a third-generation antifolate is the front-line standard of care whereas any second-line treatment was approved for MPM thus making it a pathology that evokes the need for new therapeutic agents. Different platinum-drugs were synthesised and tested as an option for patients who are not candidates to cisplatin-based therapy. Among these, monofunctional cationic antineoplastic platinum compounds received a special attention in the last decade. Alternative strategies to the commonly used combination-therapy resulted from the use of Mesenchymal Stromal Cells (MSC) widely used in the field of regenerative medicine and recently proposed as natural carriers for a selective delivery of chemotherapeutic agents and from the use of immune checkpoint and kinase inhibitors. The present short review shed light on the recent state of art and the future perspectives relative to MPM therapy.
Malignant Pleural Mesothelioma : State of the art and advanced cell therapy / G. Facchetti, F. Petrella, L. Spaggiari, I. Rimoldi. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 142(2017 Aug 02), pp. 266-270.
|Titolo:||Malignant Pleural Mesothelioma : State of the art and advanced cell therapy|
PETRELLA, FRANCESCO (Secondo)
SPAGGIARI, LORENZO (Penultimo)
RIMOLDI, ISABELLA (Ultimo) (Corresponding)
|Parole Chiave:||Malignant pleural mesothelioma (MPM); Cisplatin derivatives; Cationic platinum complex; Pemetrexed; Mesenchymal stromal cells (MSC)|
|Settore Scientifico Disciplinare:||Settore MED/21 - Chirurgia Toracica|
Settore CHIM/03 - Chimica Generale e Inorganica
|Data di pubblicazione:||dic-2017|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.ejmech.2017.07.063|
|Appare nelle tipologie:||01 - Articolo su periodico|